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SUMMARY 
The incretin hormone Glucagon-like peptide 1 (GLP-1) requires delivery by injection for 
the treatment of Type 2 diabetes mellitus. Here, we test if the properties of 
glycosphingolipid trafficking in epithelial cells can be applied to convert GLP-1 into a 
molecule suitable for mucosal absorption. GLP-1 was coupled to the extracellular 
oligosaccharide domain of GM1 species containing ceramides with different fatty acids 
and with minimal loss of incretin bioactivity. When applied to apical surfaces of polarized 
epithelial cells in monolayer culture, only GLP-1 coupled to GM1-ceramides with short- 
or cis-unsaturated fatty acids trafficked efficiently across the cell to the basolateral 
membrane by transcytosis. In vivo studies showed mucosal absorption after nasal 
administration. The results substantiate our recently reported dependence on ceramide 
structure for trafficking the GM1 across polarized epithelial cells and support the idea 
that specific glycosphingolipids can be harnessed as molecular vehicles for mucosal 
delivery of therapeutic peptides.    
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INTRODUCTION 
One of the major difficulties in effectively treating Type II diabetes and other chronic 
diseases involves patient compliance for life-long management by frequent injections of 
therapeutic peptides or proteins. Two of the most potent therapeutic peptides used to 
control blood glucose in Type II diabetes, insulin and analogues of the incretin hormone 
GLP-1, are impermeant to epithelial barriers at mucosal surfaces and require delivery 
by subcutaneous (SC) injection. Optimal control of blood sugar levels by these agents 
entails frequent daily injections, which can be sometimes missed by patients due to 
lifestyle and the social stigma of self-injection in public. Thus, much effort has gone into 
the development of technologies to render these therapeutic peptides absorbable 
across mucosal surfaces for efficient delivery without self-injection and with improved 
patient compliance. Here, we test if our recent discoveries on glycosphingolipid 
trafficking in polarized epithelial cells [1, 2] can be applied to convert GLP-1 into a 
molecule suitable for mucosal absorption. 
 
The gastrointestinal, respiratory, and genitourinary tracts represent vast mucosal 
surfaces where host tissues are separated from the environment only by a delicate but 
highly effective single layer of columnar epithelial cells, joined by tight junctions that are 
impermeable to proteins and even small peptides. Proteins non-specifically taken up 
into the epithelial cell by endocytosis are generally transported to lysosomes for 
degradation, establishing an effective barrier to uncontrolled entry of these materials 
into the body and the maintenance of systemic homeostasis. So far, the lack of rational 
and efficient methods to circumvent this barrier has prevented the application of most 
therapeutic proteins for efficient mucosal drug delivery. 
 
Glucagon-like peptide-1 (GLP-1) is an incretin hormone derived from the transcription 
product of the pro-glucagon gene and is primarily released from L-cells of the intestinal 
mucosa [3]. This hormone has lasting and potent antihyperglycemic actions by inducing 
glucose-dependent stimulation of insulin secretion while suppressing glucagon 
secretion, as well as restoring glucose sensitivity of pancreatic β-cells while it inhibits 
gastric secretion and motility to protract carbohydrate absorption and contribute to 
satiety [4]. Once in the circulation, GLP-1 is rapidly degraded (with a half-life of less 
than two minutes). Thus, the majority of pharmaceutical approaches have been focused 
on developing longer-acting analogues of GLP-1 [5]. Exenatide, a synthetic form of the 
peptide exendin-4 from lizard saliva, is a potent GLP-1 receptor (GLP-1R) agonist on 
the market for Type 2 diabetes [6] and even has been developed into a once-weekly 
formulation by encapsulation in Poly-(D,L-Lactide-Co-Glycolide) Microspheres [7, 8]. 
Another marketed example is liraglutide, an acylated human GLP-1 analogue [9]. 
Although these degradation-resistant GLP-1R agonists are excellent agents for the 
treatment of diabetes, they still require daily to weekly delivery by injection. Developing 
an oral long-acting GLP-1 formulation would allow patients to manage their blood 
glucose levels by a non-parenteral form of administration.  
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We recently discovered that the structure of the ceramide domain of the 
glycosphingolipid GM1, the receptor for cholera toxin that mediates cell entry, dictates 
intracellular trafficking and the subcellular localization of this lipid in mammalian cells [1, 
2]. GM1 is comprised of two major domains: the hydrophilic oligosaccharide head group 
that protrudes from the cell membrane into the extra-cellular space; and the 
hydrophobic ceramide lipid tail that anchors the molecule within the membrane bilayer. 
Native GM1 ceramides in human cells show heterogeneity in structure, most typically in 
length of the fatty acid carbon chain and degree of saturation [10].  
 
When exogenously applied to epithelial cells, the GM1-ceramide species that contain a 
short chain C12:0 or an unsaturated C16:1 fatty acid in the ceramide domain enter the 
early sorting/recycling endosome from where they are sorted to other destinations [1]. 
The GM1-ceramide species with long, saturated C18:0 fatty acyl chains are transported 
instead to the lysosome, presumably for degradation. In simple polarized epithelial cells 
that form the single-cell thick monolayer lining mucosal surfaces, exogenously added 
GM1 species with short or unsaturated ceramide domains are transported from the 
apical (luminal) membrane across the cell to the basolateral (serosal) membrane by 
transcytosis, following a transcellular pathway leading to absorption [2].  
 
Here, we test if GM1 can be used as a molecular carrier to deliver analogues of GLP-1 
across epithelial barriers by harnessing these properties of endogenous sphingolipid 
trafficking. We linked the GLP-1 peptide to the extracellular domain of different GM1 
species with ceramide domains of known structure, synthesized as described before [1]. 
We found that ceramide-directed trafficking remained intact after GM1 attachment to a 
therapeutic analogue of GLP-1. Fusion molecules with short- or cis-unsaturated 
ceramide domains entered epithelial cells by endocytosis, trafficked to the recycling 
endosome, and reached the basolateral membrane of polarized cells by transcytosis; 
suggesting that specific glycosphingolipids may, indeed, be harnessed as molecular 
vehicles for mucosal delivery of therapeutic peptides. 
 
MATERIALS AND METHODS 
 
Materials and Reagents 
Defatted bovine serum albumin (df-BSA), fetal bovine serum (FBS), Hank’s balanced 
salts solution (HBSS) and 2-nitrophenyl β-D-galactopyranoside were from Sigma-
Aldrich (St. Louis, MO). Steadylite reagent was from PerkinElmer (Boston, MA), the 
Cytotox ONE™ kit from Promega (Madison, WI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) from Invitrogen (Eugene, OR). The plasmids 
encoding the human GLP-1 receptor (GLP-1R), the CRE6X-LUC reporter gene and β-
galactosidase were kind gifts of Alan S. Kopin (Tufts, Boston, MA), and have been 
described previously [11, 12].  
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GM1 containing C18:0 fatty acids were extracted from bovine brains using the method 
of Folch [13] and purified by ion exchange and reversed-phase chromatography. GM1 
variants were provided by Prof. S. Sonnino (Italy) and were prepared essentially as 
described in [1]. Synthesis of the GLP-1 analogue (GLP-1* Figure 1) was performed by 
New England Peptide NEP (MA, USA) by solid phase peptide synthesis. 
 
Synthesis of GLP-1* -GM1 Structural Variants 
Gangliosides were labeled via the oligosaccharide head group following a modified 
method from [1]. The glycerol side chain of the sialic acid of GM1 (2 µmoles) was 
oxidized with 2 mM sodium periodate in 100 mM sodium acetate pH 5.5, 150 mM 
sodium chloride for 30 min on ice, and the reaction quenched with glycerol. The 
oxidized ganglioside was then desalted by Bond Elut reverse phase cartridge as 
previously described [1].  
Conjugation of GM1 to GLP-1* and subsequent purification was performed by New 
England Peptide NEP (MA, USA). Briefly, 2 μmoles oxidized ganglioside were 
resuspended in phosphate buffered saline pH 7.4 (PBS) and reacted with 6 µmol (1:3 
ratio) GLP-1* in PBS containing 100 mM aniline for 16 hours. The coupled GLP-1*-GM1 
analogues were purified by preparative RP-HPLC on a YMC C-18 column (250 × 4 mm, 
5 μm, Shiseido, Japan) using a mobile phase of 10 mM aqueous ammonium acetate 
(eluent A) and 10 mM ammonium acetate in 80% acetonitrile and 20% water (eluent B). 
Products were confirmed using MALDI-TOF-MS (Biosystems Voyager-DE; PE 
Biosystems, Foster City, CA) using a matrix solution of 10 mg/mL alpha cyano 4-
hydroxycinnamic acid in 50/50 eluent A/B. Mass spectra were recorded in linear mode, 
with either positive-ion or negative-ion TOF detection using an accelerating voltage of 
20 kV. Purity was assessed by SDS-PAGE analysis as described in the Supplemental 
Materials and Methods.  
 
Bioactivity assay 
Bioactivity of GLP-1* and all GLP-1*-GM1 fusion molecules was assayed in HEK293 
cells expressing the hGLP-1 receptor and a luciferase-CRE reporter for cAMP 
described in [11, 12, 14, 15]. In brief, HEK293 cells plated at a density of 2000–3000 
cells per well in clear-bottom, white 96-well plates were transiently transfected using 
Lipofectamine® reagent (Invitrogen, Carlsbad, CA) with cDNAs encoding (1) hGLP-1-R, 
(2) the CRE6X-LUC reporter gene and (3) β-galactosidase. Twenty four hours after 
transfection, cells were incubated with different concentrations of free peptide or a 
fusion molecule in serum-free medium with df-BSA for 4 h. Following ligand stimulation, 
cells were lysed and luciferase activity was quantified after addition of Steadylite 
reagent using a Victor X3 2030 Multilabel Reader (PerkinElmer, Boston, MA). A β-
galactosidase assay was performed after adding the enzyme substrate 2-Nitrophenyl β-
D-galactopyranoside, and incubating at 37C for 15–45 minutes. Substrate cleavage 
was quantified by measurement of optical density at 420 nm using a SpectraMax 250 
microplate reader (Molecular Devices, Sunnyvale, CA). Corresponding values were 
used to normalize the luciferase data for transfection efficiency. Results were analyzed 
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using non-linear regression techniques with GraphPad Prism v5.00 (San Diego, 
California, USA), which was used to determine the ED50.  
 
Trafficking in A431 Cells 
Stable A431 cell lines expressing EGFP markers were plated on 18 mm coverslips two 
days prior to the incubation. Cells were washed in 37 ºC Hank’s Balanced Salt Solution 
(HBSS) and equilibrated with df-BSA in HBSS for 10 min. Cells were incubated for 1 - 2 
h at 37 ºC with GLP-1*-GM1 lipids at 0.2-2.0 µM concentrations in a molar ratio of 1:10 
(lipid:df-BSA). Cells were then washed with 37 ºC HBSS with 1% df-BSA and then 
washed with PBS before fixation with 4% paraformaldehyde (Electron Microscopy 
Sciences) for 20 min at room temperature. All remaining steps were performed at room 
temperature in a humidified chamber. After quenching the paraformaldehyde with 50 
mM ammonium chloride and several washes with PBS, cells were permeabilized with 
0.05% saponin in PBS for 30 min. The cells were then incubated with streptavidin-
Alexa568 (Invitrogen) diluted at 1:200 in 0.01% saponin in PBS for 30 minutes. 
Preparations were mounted in anti-fade medium Mowiol and imaged by confocal 
microscopy. 
 
Polarized Epithelial Trafficking 
MDCK II cells plated on 24-well Transwell® inserts (0.4 µm, polyester membranes, 
Costar) were washed and equilibrated in DMEM containing df-BSA prior to apical 
addition of GLP-1*- GM1 fusion molecules at 0.2 - 4.0 µM complexed to df-BSA in a 
1:10 ratio or free peptide. In continuous studies, cells were incubated with the 
compounds for 3 h at 37 C. In the pulse-chase studies, cells were incubated for 1 h 
with GLP-1*-GM1 compounds at 37 C prior to exchange with DMEM followed by a 3 h 
chase. Control cells were incubated for 10 min at 37 C, after which they were placed at 
4 C for the remaining incubation time. A similar protocol was performed for T84 cells, 
which were plated on 24-well Transwell® inserts (3.0 µm, polyester membranes, 
Costar) and all incubations were performed in T84 medium (without serum). Only high 
electrical resistance T84 monolayers or MDCK II cells that kept their resistance during 
the experiments were included in this study.  
For transcellular detection of GLP-1*-GM1 fusion molecules in polarized epithelial cells, 
an excess of BSA (1% wt/vol) was added basolaterally to aid in the extraction of lipids 
from the basolateral surface. At the end of incubations, the basolateral media was 
collected and the amount of GLP-1* or GLP-1*-GM1 fusion molecule in the media were 
determined by the bioactivity assay described above with concentrations calculated 
from a standard curve.  
For cell imaging, cells were washed after the incubation with 37 ºC HBSS with 1% df-
BSA and then PBS before fixation with 4% paraformaldehyde (Electron Microscopy 
Sciences, PA) for 20 min at room temperature. All remaining steps were performed in a 
humidified chamber. After several washes with PBS, the cells were incubated with 
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streptavidin- Alexa 568 (Invitrogen) diluted at 1:100 in PBS and incubated overnight at 4 
C. After extensive washes with PBS, the cells were mounted in the anti-fade medium 
Mowiol. 
 
In vivo studies 
WT C57BL/6 mice (male, 6-9 weeks old) were purchased from Jackson Laboratory 
(Maine, USA). These mice have a naturally occurring deletion in the nicotinamide 
nucleotide transhydrogenase gene, which results in impaired glucose-stimulated insulin 
secretion [16]. Animals were acclimatized for 2 weeks and housed under a 12 h 
light/dark cycle and allowed food and water ad libitum. The nasal in vivo activity was 
evaluated using an oral glucose tolerance test (OGTT). Briefly, mice that had been 
fasted for 18 h, were lightly anesthetized with isoflurane and 20 μL of GLP-1* or GLP-
1*-GM1 C16:1 (various concentrations) or saline was slowly dripped into the nasal 
cavity. After 1 h, mice were injected a 2 g /kg dose of glucose (n = 2 each). Blood 
glucose levels were determined at given times in approximately 5 μL whole blood 
obtained from tail nick using a one-touch blood glucose meter (Contour, Bayer 
Healthcare, IN, USA) and area-under-the-curve (AUC) values were calculated using 
GraphPad Prism v5.00 (San Diego, California, USA). 
 
RESULTS and DISCUSSION 
Synthesis and characterization of GLP-1 analogues and GLP-1-GM1 fusion 
variants 
We synthesized a stable GLP-1 analogue containing -amino-isobutyric acids (Aib) at 
residues 8 and 33 to allow for increased half-life [17] (Figure 1A). The peptide was 
extended at the C-terminus to incorporate a short linker sequence followed by two 
modified lysine residues. The penultimate amino acid contained a biotin molecule linked 
via a 0.5 kDa PEG spacer, allowing us to track the molecule biochemically and by 
microscopy. The terminal amino acid contained the same PEG spacer ending with an 
aminooxy group for coupling to the extracellular oligosaccharide domain of GM1 (Figure 
1A).   
 
To allow, in theory, for cleavage and release of the GLP-1 analogue from GM1 after 
transcytosis, we designed the peptide to include one of the several subtilisin-related 
endoprotease furin cleavage motifs [18, 19] inserted between GLP-1 and the terminal 
amino acids of a linker-sequence. The linker sequence contained the biotin and 
aminoxy reactive group for fusion to GM1 (illustrated in green, Figure 1A). Furin 
processes a wide range of bioactive proteins and localizes, among other intracellular 
organelles, to the basolateral surface of polarized epithelial and endothelial cells [20, 
21]. When tested in vitro, however, the GLP-1 linker peptide was resistant to cleavage 
by the furin protease (Figure S1); perhaps due to interference with the enzyme by the 
more stably coiled structure of the GLP-1 analogue with its Aib residues [17], or due to 
the additional PEG groups and/or biotin blocking the furin recognition site. Thus, despite 
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our intentions, the peptide and GM1 sphingolipid domains in this design remained stably 
fused. Throughout this paper, we refer to the PEGylated analogue peptide as GLP-1* 
and to the fusion molecule as GLP-1*-GM1. 
 
 
Figure 1. Characterization of GLP-1*-GM1 fusion molecules. (A) Structures of GLP-1* (left 
panel) and GM1 (right panel). The different GM1 acyl chains (R) and functionalized lysyl-PEG 
linkers (Kx, Ky) are indicated. (B) GLP-1*-GM1 fusion molecules retain functional activity. The 
activities were determined by an in vitro assay for peptide-induced cAMP using HEK293 cells 
expressing the hGLP-1 receptor measured in triplicate (error bars represent mean ± SEM). (C) 
Table of the EC50 values as determined in (B) as mean ± SD for at least 4 separate 
experiments. (D) Optimizing conditions to obtain equally loaded GLP-1*-GM1 cell membranes. 
FACS analysis of A431 cells loaded with GLP-1*-GM1 as indicated for 10 min, post-trypsin 
wash (blue trace). Cells were incubated with streptavidin-Alexa488 and fluorescence was 
measured in the FITC-A channel. Control cells not loaded with GM1 are shown in red (Fmean = 
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75.4). At the indicated concentrations, the cells loaded with C12:0, C16:1 or C18:0 GM1 fusions 
showed equal fluorescence (blue traces), while the free peptide did not bind detectably to the 
cells (quantification from at least two separate experiments corrected for background are shown 
in (E) as mean ± SEM). (F) Immunoblot of lysates from polarized MDCK monolayers incubated 
for 10 min with GLP-1*-GM1 fusion molecules at 0.25 µM C16:1, 0.2 µM C12:0 and 2 µM C18:0 
(post-trypsin wash). Immunoblots were probed with neutravidin-HRP and a representative of 
two independent experiments is shown. 
 
GM1 was oxidized on the sialic acid to generate a reactive aldehyde group to conjugate, 
via oxime ligation, to the aminooxy side chain engineered into the peptide. GLP-1* was 
fused to GM1 species synthesized to contain either a short saturated 12-carbon fatty 
acyl chain (C12:0), a single unsaturated 16-carbon acyl chain (C16:1), or a long 
saturated 18-carbon acyl chain in the ceramide domain (C18:0) (Figure 1A).  
 
The structures of all fusion molecules were confirmed by mass spectrometry (Figure S2) 
and their purity by gel analysis and densitometry (Figure S3 A and B). With the 
exception of the C12:0 molecular species, the GM1 species synthesized are naturally 
occurring lipids [10, 22]. The molecules did not induce significant cytotoxicity in MDCK II 
cells after 3 h of continuous incubation as assayed by transepithelial resistance and 
LDH release (Figure S3 D). Neither was any significant cytotoxicity observed after 24 h 
observed by LDH release or MTT metabolism (Figure S3 D and E), an incubation time 
far exceeding the conditions of our assay. All fusion molecules were shown to retain 
bioactivity of the GLP-1 component as assessed in vitro using HEK293 cells expressing 
the hGLP-1 receptor, with an ED50 for the GM1 C12:0 and C16:1 fusions of only 10-fold 
less than the native peptide, and still with picomolar efficacy (Figure 1B-C). The GM1 
C18:0 fusion was approximately one and a half-log (40-fold) less active, implicating 
interference by the more hydrophobic nature of this fusion molecule. Other groups have 
observed similar decreases in potency when single or dual linked simple fatty acids 
were attached to a GLP-1 analogue, with very long fatty acids decreasing potency [23].  
 
Conditions for loading cells equally with the different GLP-1*-GM1 fusion molecules 
were determined in A431 cells by fluorescence-activated cell sorting (FACS) analysis 
(Figs 1D and E) or in polarized canine kidney MDCK monolayers by Western Blot (Fig 
1F). Analysis of GM1 membrane uptake was done after treatment with trypsin, which 
was used as reported to remove any fusion molecules adhering to the cell but not 
specifically integrated into the membrane bilayer [1, 24, 25] (Figs 1D-F). In principle, 
only lipids properly incorporated into the membrane bilayer will traffic according to the 
structure of the ceramide domains in live cells. Equal membrane incorporation of the 
GLP-1*-GM1 fusion molecules in A431 cells were observed in a 1:1.25:8 ratio for the 
C12:0, C16:1, and C18:0 species respectively. Applying the same ratio for loading 
MDCK cells resulted in a higher incorporation of C12:0 species in comparison to C16:1 
or C18:0, but, the levels of incorporation of the C16:1 and C18:0 fusion molecules were 
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closely comparable. A 10-fold molar excess of defatted bovine serum albumin (df-BSA) 
was used to optimize membrane loading in A431 or MDCK cells (Figure S4).  
 
Influence of peptide coupling on GM1 intracellular trafficking 
To test if the different GM1 ceramide domains directed intracellular trafficking of the 
GLP-1*-GM1 fusion molecule as predicted from our earlier results [1], we applied the 
fusion proteins to A431 cells stably expressing EGFP-fusions to Rab11a, and Rab7 
GTPases that mark the recycling (RE), and late endosomal compartments (LE) 
respectively. The fraction of GLP-1*-GM1 occupying each sub-cellular compartment in 
three dimensions was quantified relative to total GLP-1*-GM1 incorporated into the cell 
using the Manders colocalization coefficient (termed Mx, as described in supplemental 
materials and methods [1, 26]). Both GLP-1*-GM1 C12:0 and C16:1 fusion molecules 
entered the recycling endosome of epithelial cells (Rab11a compartment) (Figure 2A 
and quantified on plot to right). Less of the C18:0 fusion molecules reached this 
compartment, and more C18:0 was localized in late endosomes (Rab7, Figure 2B) 
compared to C12:0 and C16:1. These results are fully consistent with our earlier studies 
on trafficking Alexa-GM1 [1]. Thus, the biology and influence of ceramide structure on 
GM1 trafficking remains intact after attachment to a therapeutic analogue of GLP-1. 
 
GM1 sphingolipids as transport vehicles across epithelial barriers 
To test for transcytosis, GLP-1*-GM1 fusion molecules were introduced into apical 
membranes of polarized canine kidney MDCK monolayers and analyzed for transport to 
the basolateral membrane by confocal microscopy. The GLP-1*-GM1 C12:0 and C16:1 
fusion molecules were found on basolateral membranes after 3 h at 37C (Figure 3A, 
2nd and 3rd rows). Localization to the basolateral membrane was specified using wheat 
germ agglutinin (WGA) to stain opposing apical membrane glycoproteins (Supplemental 
Fig S5), and by using MDCK cells expressing EGFP-tagged FcRn, a Fc-trafficking 
receptor that localizes at steady state primarily to the cell interior (Supplemental Fig S6). 
No basolateral membrane localization was detected in control monolayers loaded 
apically with the free peptide GLP-1* (Fig 3A top row) or with the GLP-1*-GM1 C12:0 
fusion molecule incubated with cell monolayers for 10 min and then shifted to 4°C (Fig 
3A bottom row). These results indicate that transcellular glycosphingolipid transport 
from apical to basolateral cell surfaces was by transcytosis and not by paracellular 
diffusion through tight junctions. In contrast to the GLP-1*-GM1 C12:0 and C16:1 fusion 
molecules, we found barely detectable amounts of the GLP-1*-GM1 C18:0 species 
localized to basolateral membranes (Figure 3A, 4th row); even though comparable levels 
were initially associated with the apical PM before transport (Figure 1F). Thus, 
transcellular transport depends on ceramide structure of the GM1 sphingolipid carrier, a 
result consistent with our earlier studies [2].   
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Figure 2. Intracellular Distribution of the Different GLP-1*-GM1 fusion molecules. (A and 
B) Confocal images of fixed A431 cells stably expressing EGFP fusion proteins as indicated. 
Cells were incubated 2 h with GLP-1* labeled GM1 (0.2 µM C12:0, 0.25 µM C16:1 or 2 µM 
C18:0) or free peptide (2 µM). After washing, the cells were fixed and stained with streptavidin-
Alexa568 to label the fusion molecule via biotin (red). Inverted grayscale images of selected 
areas (dotted box) for individual fluorescence channels are shown to the right of the merged 
images. Histograms (far right) show quantitation of GLP-1*-GM1 localized to the respective 
compartment using Manders (Mx) coefficients for at least three independent experiments. Each 
dot represents a correlation coefficient calculated from a single field of view containing 2–3 cells 
on average. Scale bars = 10 µm (ns stands for p > 0.05, *** stands for p ≤ 0.001). 
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Figure 3. Polarized epithelial cells sort the GLP-1*-GM1 fusion molecules into the 
transcytotic pathway based on structure of the ceramide domain and the amount GLP-1*-
GM1 reaching the basolateral surface is concentration dependent. The controls with free 
peptide or placed at 4C do not show basolateral membrane staining, nor does GLP-1*-GM1 
C18:0. (A) Polarized epithelial monolayers of MDCK cells were continuously incubated apically 
for 3 h at 37C with GLP-1* labeled GM1 (0.4 µM C12:0, 0.5 µM C16:1 or 4 µM C18:0), or free 
peptide (0.4 µM) (B) or pulse labeled apically with GLP-1*-GM1 C16:1 (concentrations as 
indicated) at 37C for 1 h and then chased for 3 h. After washing, cells were fixed and stained 
with streptavidin-Alexa568. Illustrated are confocal images of the apical membrane, basolateral 
signal at ~1 µm up from the membrane support (small panels above are XZ reconstructions), 
and a zoom of the basolateral image. Unlike the GLP-1*-GM1 C12:0 and C16:1 fusion proteins, 
the GLP-1*-GM1 C18:0 does not visualize at the apical membrane at 3 h incubations because it 
is trafficked away from the recycling endosomes to the late endosome lysosome pathway. Data 
are representative of 5 independent experiments for A and 4 for B. Scale bars = 10 µm. (C-D) 
Quantification of the basolateral fluorescent signal at ~1 µm up from the membrane support of 
images obtained in experiment A and B. Each dot represents a single field of view containing 30 
cells on average and between 5 - 9 images were analyzed (mean ± SEM).  
 
We next tested for the membrane topology of GM1 transport to confirm that the GLP-1* 
peptide was delivered to the extra-cytoplasmic surface of the basolateral membrane 
and available to the extracellular basolateral (serosal) space after transcytosis. To do 
this, the basolateral membrane of live MDCK monolayers were stained at 4°C with 
streptavidin-Alexa568 after their apical 37°C incubation with GLP-1*-GM1 C16:1. At 
4°C, membrane traffic is stopped, cell membranes and tight junctions remain intact, and 
streptavidin can bind only if the GLP-1* peptide containing biotin is exposed on the 
extracellular surface of the basolateral membrane. The results show that streptavidin 
bound to basolateral membranes of MDCK monolayers incubated with GLP-1*-GM1 
C16:1 (Figure S7). No labeling was observed for monolayers treated with the GLP-1* 
peptide, or if incubated with the GLP-1*-GM1 C16:1 fusion molecule for just 10 min at 
37°C to allow loading of the apical membrane (Fig S7, upper and lower rows).  
 
The amount of GLP-1*-GM1 fusion molecule transported to the basolateral surface was 
concentration dependent, as assessed using the GLP-1*-GM1 C16:1 species (Figure 
3B). Similar results were obtained for the C12:0- and C16:1-containing GLP-1*-GM1 
fusion molecules applied to polarized human intestinal T84 cells in monolayer culture, 
although higher concentrations had to be applied to obtain lipid-uptake and detectable 
transport in T84 cells (Figure 4A and B, and see [2]). Based on these studies, we 
conclude that the GM1 sphingolipids with short or unsaturated ceramide domains can 
act as molecular carriers for transcellular transport of therapeutic peptides across 
barrier epithelial cells.  
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Figure 4. GLP-1*-GM1 crosses to the basolateral membrane of T84 monolayers by 
transcytosis. The controls are monolayers incubated with free peptide or with GLP-1*-GM1 at 
4C and do not show a basolateral membrane staining. T84 cells grown on a membrane support 
were pulse labeled apically at 37C for 1 h and then chased for 3 h with GLP-1* labeled GM1 
C12:0, C16:1 or free peptide at 1 µM (A) or with varying concentrations of GLP-1*-GM1 C16:1 
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(concentrations as indicated, B). After washing, the cells were fixed and stained with 
streptavidin-Al568. Illustrated are a confocal image of the apical membrane, basolateral signal 
at ~2um up from the membrane support (small panels above are XZ reconstructions), and a 
zoom of the basolateral image. Data are representative of three independent experiments. 
Scale bars = 10 µm. (C-D) Quantification of the basolateral fluorescent signal at ~2 µm up from 
the membrane support of images obtained in experiment A and B. Each dot represents a single 
field of view containing 45 cells on average and between 6 - 7 images were analyzed (mean ± 
SEM). 
 
To confirm these results, we tested for transcytosis in another way by measuring the 
amount of GLP-1*-GM1 fusion molecules released from the basolateral membrane of 
MDCK monolayers to the basolateral media after an apical application. Initial studies 
showed that both the GLP-1*-GM1 C12:0 and C16:1 fusion molecules and the GLP-1* 
peptide, crossed the epithelial monolayer to the basolateral reservoir. This result was in 
contrast to our findings using confocal microscopy and suggested a non-specific 
paracellular-leak pathway for crossing the monolayer by the GLP-1* peptide. To test this 
possibility, we studied paired monolayers incubated continuously with GLP-1* or GLP-
1*-GM1 peptides (Figure 5A). For the GLP-1*-GM1 fusion molecules, transport from 
apical to basolateral reservoirs was strongly inhibited by incubation at 4°C, consistent 
with transcellular transport by transcytosis. In contrast, transcellular transport of the 
GLP-1* peptide (when not fused to GM1) remained robust during incubations at 4°C 
(nearly equal to the levels seen after continuous 37°C incubations) (Figure 5A). This 
result implicates transport of GLP-1* across the monolayer by paracellular leak. Such 
paracellular transport for the GLP-1* peptide would not have been detected by confocal 
microscopy as the free peptide would have been washed away before fixation. How the 
GLP-1* peptides can traverse intact tight junctions, however, remains unexplained. In 
principle, tight junctions should be impermeant to peptides the size of GLP-1* [27, 28]. It 
is possible the appended PEG chains and biotin somehow increases paracellular 
permeability as previously suggested for the mucosal absorption of PEGylated- or 
biotinylated-GLP-1 peptides observed in mice [29-32].   
 
We obtained similar results when testing for proof of principle in vivo by nasal 
applications of GLP-1* and GLP1*-GM1 C16:1. In these studies, the extent of systemic 
uptake of the peptide or GM1-fusion molecules was monitored functionally by glucose-
tolerance test. Nasal application of GLP-1*-GM1 C16:1 effectively enhanced clearance 
of blood glucose by 5-fold with apparent EC50 of 5 nanomoles/kg (Figure 5B, closed 
squares), indicating absorption. But, we also found evidence for absorption of the free 
GLP-1* peptide (Figure 5B, open circles), presumably by paracellular leak as indicated 
by our in vitro studies (Figure 5A). Our interpretation is that the GLP-1*-GM1 C16:1 
fusion molecule is absorbed at or above background levels. In this assay, we cannot 
discern the efficiency of absorption between the two because the free-peptide is 10-fold 
more biologically active, and we lack a measure for delivery to the mucosal surface of 
the respiratory tract. The GLP-1*-GM1 fusion is larger, more hydrophobic, and likely 
more interactive with mucus in the extracellular space than the GLP-1*, so it could be 
15 
 
less efficient in accessing the nasal epithelium after topical application when 
administered from simple aqueous formulations. Thus, we can conclude only that the 
GLP-1*-GM1 fusion molecule can be mucosally absorbed. 
Figure 5. Fusion molecules have similar efficacies as the free peptide. (A) The cells were 
incubated at 37C for 3 h with free peptide (0.4 µM) or GLP-1* labeled GM1 C12:0 (0.4 µM) or 
C16:1 (0.5 µM). The concentration of molecules in the basolateral media was determined based 
on their activities in the in vitro assay described in Fig. 1B, measured in triplicate (error bars 
represent mean ± SEM). ns stands for p > 0.05, * stands for p ≤ 0.05 and ** stands for p ≤ 0.01. 
(B) The 10-fold lower activation of the hGLP-1 receptor by GLP-1*-GM1 fusion molecules 
compared to GLP-1* (Figure 1B) is preserved in their nasal hypoglycemic efficacy. Dose-
response curves of different concentrations of free peptide or GLP-1*-GM1 C16:1 fusion 
molecules that were nasally applied to mice. Displayed are the areas under the curve of glucose 
tolerance curves. (n = 2, mean ± SD). 
 
Overall, these studies show that GM1 can act as a vehicle for transepithelial transport of 
a 5 kDa therapeutic peptide across a simple epithelial barrier. We find that trafficking 
cargo across polarized epithelial cells depends on the specific structure of the GM1 
ceramide domain, as predicted by our earlier studies using the same GM1 species 
labeled with small molecule fluorophores. The underlying cell biology for 
glycosphingolipid transport remains intact after fusion to the GLP-1 peptide; supporting 
the feasibility of using specific glycosphingolipids as molecular carriers to deliver 
biologically active therapeutic agents across mucosal surfaces. This approach is distinct 
from the use of fatty acid lipidation of a therapeutic peptide to improve metabolic 
stability or membrane permeability and thus bioavailability [33-35]. Linkage to specific 
species of GM1 takes advantage of a native ganglioside transcytosis trafficking 
pathway, providing a novel and previously unappreciated approach of integrating the 
biology of subcellular sphingolipid trafficking to enhance transmucosal delivery as an 
element of drug design [36].  
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Our results, however, also suggest several problems that will need to be overcome for 
this approach to achieve therapeutic utility. First, we found there was no detectable 
advantage for transcytosis of the GM1-fusion molecules over paracellular leak of the 
free-peptide when tested in vitro. PEGylation and biotinylation of the free GLP-1* 
peptide, in this case, may have allowed for enhanced transport across tight junctions 
[29-32], strongly confounding our biochemical in vitro results. Other factors may also 
have been in operation to make the active transcytotic pathway appear only marginally 
better than non-specific transport by passive paracellular leak. For example, the GM1 
sphingolipid acts as a trafficking molecule because it inserts into the membrane as a 
normal glycosphingolipid, explaining how the structure of the ceramide chain can affect 
lipid sorting. In doing so, however, the ceramide domain effectively tethers the peptide 
to the membrane. Release into solution after transcytosis from the basolateral 
membrane as desired is expected to be restricted – the molecule will be in equilibrium 
with the membrane bound and soluble state, with a strong affinity to remain membrane 
associated. Technology to release the peptide from the membrane after transcytosis is 
predicted to enhance vectorial transport. It is possible that incorporation of furin 
cleavage motifs into the peptide linker will achieve this aim, though we were not able to 
test this idea with the current construct. Another potential problem is that incorporation 
of the GM1-fusion peptides into the apical membrane of epithelial cells lining mucosal 
surfaces may not have been highly efficient [1]. Here, formulations of the fusion 
molecules with carrier molecules or with amphipathic hydrogels or emulsions might 
enhance membrane incorporation.  
 
Our interest in GM1 as a vehicle for drug delivery originated from our studies on the 
intracellular trafficking of this lipid as a receptor for cholera toxin [1]. We exploit the 
newly discovered biology of GM1 to achieve this aim, but also note the longstanding 
interest in utilizing GM1 in drug development. Indirectly, GM1 has been used as a 
vehicle for delivery of oral vaccines and the induction of mucosal immune responses via 
coupling antigen to the binding B subunit of cholera toxin [37]. Exendin-4, a GLP-1 
analogue, has been expressed as a cholera toxin B subunit–fusion protein to facilitate 
transmucosal delivery in the gut via toxin binding to GM1 [38]. Vaccine antigens have 
also been coupled to peptides with affinity for GM1 to enhance uptake with variable 
success [39, 40]. Other glycosphingolipids have also been used to attach 
immunoglobulins to liposomes to pursue antibody-mediated targeting of vesicles to cells 
[41]. Thus, the biology of GM1 sphingolipids has engaged the interest of 
pharmacologists in the past. 
 
Here, we show that specific GM1 ceramide structures can be used to direct the 
transcytosis of a biologically active, therapeutic cargo. There are still technological 
challenges to overcome for translation of this finding into clinical applications. And we 
do not yet know if GM1 is the only glycosphingolipid exhibiting these properties. It is 
possible that simplified glycosphingolipids containing ceramides with short or 
unsaturated fatty acids might traffic through the same pathways, rendering the complex 
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oligosaccharide domain of GM1 dispensable. Nonetheless, our results show it feasible 
to harness the biology of glycosphingolipid trafficking across simple polarized epithelial 
cells for mucosal absorption of therapeutic peptides and for other clinical applications.  
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